NCE-1 Intelligence & Market Opportunity

Vtama

Tapinarof

Dermatologic

Topical Cream

Approval Date

23-May-22

NCE-1 Date

23-May-26

NCE Date

23-May-27

Commercial snapshot

Market performance & projections

Revenue ($M)

128

CAGR (%)

0.2841

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

180

2027

246

2028

301

2029

348

2030

393

2031

439

2032

482

Molecule profile

Details & specifications

Molecule

Tapinarof

Innovator

ORGANON LLC

Dosage Form

Topical Cream

Strength

0.01

Therapeutic Category

Dermatologic

Usage

To treat plaque psoriasis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.